drug delivery

Patients

Jonah Comstock at AAPS interviewing Mehul Desai

Challenging conventional wisdom on injectables, with Mehul D...

Mehul Desai, VP of medical affairs at Enable Injections, sat down with pharmaphorum editor-in-chief Jonah Comstock at AAPS.

News

GSK makes fresh neuroscience foray with £2bn+ ABL deal

Neuroscience isn't listed as one of the top R&D priorities at GSK, but a new alliance with ABL Bio adds to the sense that its focus may be shifting.

News

Graphical representation of Brainshuttle antibody at the blood-brain barrier

Roche preps phase 3 for 'Brainshuttle' Alzheimer's drug

Buoyed by data from a phase 1b/2a trial, Roche has said it plans to start a phase 3 programme for an Alzheimer's drug from its Brainshuttle programme.

News

MSD says subcutaneous Keytruda matches IV form

A formulation of MSD's cancer drug Keytruda that can be given by subcutaneous injection rather than intravenous infusion has cleared a phase 3 trial.

News

Woman injecting herself while sat at a table

MIT team develops 'years-long' drug delivery tech

Researchers in the US have devised a new depot system that could provide months or even years of delivery from a single subcutaneous injection.

News

AstraZeneca buys cell therapy biotech for up to $1bn

AstraZeneca plans to acquire Belgian in vivo cell therapy biotech EsoBiotec and has signed a pair of licensing deals with drug delivery firm Alteogen.

Challenging conventional wisdom on injectables, with Mehul D...

GSK makes fresh neuroscience foray with £2bn+ ABL deal

Roche preps phase 3 for 'Brainshuttle' Alzheimer's drug

MSD says subcutaneous Keytruda matches IV form

MIT team develops 'years-long' drug delivery tech

AstraZeneca buys cell therapy biotech for up to $1bn

Remepy's hybrid Parkinson's therapy poised for phase 3

Discover a new era of healthcare panel engagement: Grounded ...

drug delivery

Editor's Picks